We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

5 hedge funds and large institutions have $2M invested in XTL Biopharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $1.69M → $2M (+$306K)

0.14% less ownership

Funds ownership: 9.39% → 9.25% (-0.14%)

17% less funds holding

Funds holding: 6 → 5 (-1)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$124

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$12K
2
SW
SteelPeak Wealth
California
-$9.3K
3
Renaissance Technologies
Renaissance Technologies
New York
-$5.54K

XTLB Hedge Fund Activity: Q2 2021 in Review

5 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2021, worth a combined $2M — up 18% from $1.69M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $124. The largest seller was UBS Group, exiting entirely with an estimated $12K sold.

  • 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2021, down from 6 in Q1 2021.
  • Funds reported $2M of XTL Biopharmaceuticals stock for Q2 2021, up 18% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q2 2021 and 1 closed out, a net change of -1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q2 2021 was Morgan Stanley, an estimated $124 added.
  • The largest XTL Biopharmaceuticals seller in Q2 2021 was UBS Group, an estimated $12K sold.

Based on aggregated 13F filings for Q2 2021.